Our Vision
To become the global leader in rapid infectious disease diagnostics.
CORPORATE OVERVIEW
Innovita Biological Technology Co., Ltd
Shaping the Future of Global Diagnostic Care
Founded in 2006 and having successfully listed on the STAR Market of the Shanghai
Stock Exchange in July 2022 (Stock Code: 688253), Innovita Biological Technology
Co., Ltd. is a high-tech corporation specializing in the research, development,
production, and sales of in vitro diagnostic (IVD) products, with a focus on rapid
point-of-care (POCT) diagnostic solutions.
As one of the leading brands in rapid infectious disease diagnostics specialized in
multiplex pathogen detection, Innovita continues to identify clinical pain points and
expand its technological capabilities across various methodologies to provide rapid
pathogen detection solutions for different application scenarios.
Corporate Social Responsibility
To combat Hong Kong's fifth COVID-19 wave in 2022, INNOVITA partnered with the DAB and donated 100,000 antigen self-test kits. This initiative addressed urgent community shortages, showcasing the global diagnostics pioneer's commitment to social responsibility and solidarity during the crisis.
In August 2021, INNOVITA and the Sunwah Group donated vital COVID-19 Antigen Test Kits to Vietnam to support local testing capabilities. Acknowledged by the Vietnamese Consulate in Kunming, this act of solidarity strengthened bilateral friendship and provided critical resources during the global pandemic.